

# Nicolas Penel

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/116349/nicolas-penel-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

242  
papers

7,941  
citations

46  
h-index

82  
g-index

309  
ext. papers

10,009  
ext. citations

4.7  
avg, IF

5.67  
L-index

#	Paper	IF	Citations
242	Sunitinib with concomitant radiation therapy in inoperable sarcomas: Final results from the dose escalation and expansion parts of a multicenter phase I study.. <i>Radiotherapy and Oncology</i> , <b>2022</b> ,	5.3	1
241	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101829	2.2	1
240	Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.. <i>European Journal of Cancer</i> , <b>2022</b> , 169, 188-197	7.5	0
239	Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. <i>European Journal of Cancer</i> , <b>2021</b> ,	7.5	5
238	Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial <b>2021</b> , 9,		1
237	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , <b>2021</b> , 10, 2645-2659	4.8	8
236	ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> ,	2.2	
235	REGOSTA: A randomized, placebo-controlled, double-blinded, multicenter study evaluating the efficacy and safety of regorafenib (REGO) as maintenance therapy after first-line treatment in patients (pts) with osteosarcoma (OS) and non-osteosarcomas (non-OS) of bone (non-Ewing, non-chondrosarcomas and non-chordomas).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS11576-TPS11576	2.2	
234	Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2565-2565	2.2	2
233	PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 11507-11507	2.2	4
232	Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 6020-6020	2.2	1
231	Prognosis value of S45F mutation of CTNNB1 in desmoid-type fibromatosis (DF): Prospective analysis of 500 consecutive patients (pts) from ALTITUDES trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 11510-11510	2.2	0
230	Determinants of the access to remote specialised services provided by national sarcoma reference centres. <i>BMC Cancer</i> , <b>2021</b> , 21, 631	4.8	3
229	Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial. <i>Value in Health</i> , <b>2021</b> , 24, 676-682	3.3	1
228	Overall survival (OS) and prognostic factors (PF) of patients (pts) with metastatic solid tumors admitted in intensive care unit (ICU).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e24074-e24074	2.2	
227	Pre-therapeutic dihydropyridimidine dehydrogenase (DPD) deficiency screening: Impact on fluoropyrimidine dose reduction at the second chemotherapy cycle and on early severe toxicity.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3096-3096	2.2	
226	Very low seroprevalence of sars-cov-2 among health care personnel (HCP) in a French northern comprehensive cancer center at the end of first national containment.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e13604-e13604	2.2	1

225	Vaccination coverage in cancer outpatients: An interventional multicenter before/after study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e24026-e24026	2.2	
224	Desmoid-type fibromatosis: toward a holistic management. <i>Current Opinion in Oncology</i> , <b>2021</b> , 33, 309-314	1.4	0
223	High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcS'pembrolizumab study from Unicancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 11520-11520	2.2	0
222	Impact of the COVID-19 pandemic on clinical activity during the lockdown in North France: A single center experience.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e13594-e13594	2.2	
221	"TNM" at study entry in phase I trials. <i>Bulletin Du Cancer</i> , <b>2021</b> , 108, 671-672	2.4	
220	Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. <i>European Journal of Cancer</i> , <b>2021</b> , 150, 108-118	7.5	3
219	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 289-298	8.9	12
218	Two cases of rare late onset life-threatening pseudoprogression with immune check point inhibitors in advanced cancer patients - a case report. <i>Acta Oncologica</i> , <b>2021</b> , 60, 683-686	3.2	
217	Major impact of COVID-19 national containment on activities in the French northern comprehensive cancer center. <i>Medical Oncology</i> , <b>2021</b> , 38, 28	3.7	1
216	Is the survival of patients treated with ipilimumab affected by antibiotics? An analysis of 1585 patients from the French National hospital discharge summary database (PMSI). <i>Oncolimmunology</i> , <b>2020</b> , 9, 1846914	7.2	2
215	ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. <i>ESMO Open</i> , <b>2020</b> , 5, e000662	6	4
214	Maintenance therapy and drug holiday in sarcoma patients: systematic review. <i>Acta Oncologica</i> , <b>2020</b> , 59, 1084-1090	3.2	5
213	Midazolam sedation in palliative medicine: retrospective study in a French center for cancer control. <i>BMC Palliative Care</i> , <b>2020</b> , 19, 85	3	2
212	Incidence and time trends of sarcoma (2000-2013): results from the French network of cancer registries (FRANCIM). <i>BMC Cancer</i> , <b>2020</b> , 20, 190	4.8	14
211	A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment. <i>Pharmacology Research and Perspectives</i> , <b>2020</b> , 8, e00613	3.1	1
210	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort <b>2020</b> , 8,		23
209	Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , <b>2020</b> , 21, 446-455	21.7	92
208	Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA). <i>BMC Cancer</i> , <b>2020</b> , 20, 117	4.8	2

207	Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 456-466	21.7	25
206	A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. <i>European Journal of Cancer</i> , <b>2020</b> , 126, 45-55	7.5	5
205	Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies. <i>Critical Reviews in Oncology/Hematology</i> , <b>2020</b> , 150, 102960	7	1
204	Epithelioid Hemangioendothelioma <b>2020</b> , 113-128		
203	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , <b>2020</b> , 127, 96-107	7.5	108
202	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1-10	2.2	786
201	Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, 295-303.e3	3.3	4
200	Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol. <i>BMJ Open</i> , <b>2020</b> , 10, e038391	3	5
199	Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 594445	5.3	7
198	Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
197	Symptomatic acute hypotension associated with high-dose dacarbazine. <i>Melanoma Research</i> , <b>2020</b> , 30, 426-428	3.3	
196	Switch in use of midazolam for cancer patients during the COVID-19 pandemic. <i>Journal of Oncology Pharmacy Practice</i> , <b>2020</b> , 26, 1817-1818	1.7	
195	Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals. <i>Cancer</i> , <b>2020</b> , 126, 4614-4615	6.4	
194	Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
193	Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 413-423	7.5	10
192	Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. <i>European Journal of Cancer</i> , <b>2019</b> , 119, 151-157	7.5	51
191	Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 141, 23-35	7	26
190	Personalised management of alveolar soft part sarcoma: a promising phase 2 study. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 750-752	21.7	0

189	Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4611-4615	12.9	6
188	Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 2135-2143	7.5	6
187	"Impossible" patients in oncology: Two unusual cases. <i>Palliative and Supportive Care</i> , <b>2019</b> , 17, 119-121	2.5	
186	Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 1263-1272	21.7	69
185	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 1109-1123	21.7	113
184	Watch and Wait Approach for Re-excision After Unplanned Yet Macroscopically Complete Excision of Extremity and Superficial Truncal Soft Tissue Sarcoma is Safe and Does Not Affect Metastatic Risk or Amputation Rate. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 3526-3534	3.1	23
183	Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 143, 62-66	7	8
182	Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient With Metastatic Undifferentiated Pleomorphic Sarcoma: Postscriptum From the T-Dis Trial. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2019</b> , 42, 737	2.7	1
181	Emerging Role of Multikinase Inhibitors in Desmoid Tumor Management. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2019</b> , 42, 958	2.7	
180	Management of tumor tissue in cancer clinical trials: An ethical perspective. <i>Bulletin Du Cancer</i> , <b>2019</b> , 106, 1064	2.4	
179	Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 120-133	21.7	134
178	Non-islet-cell tumour hypoglycaemia (NICTH): About a series of 6 cases. <i>Annales D'Endocrinologie</i> , <b>2019</b> , 80, 21-25	1.7	7
177	Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma: Long-term Follow-up of the T-DIS trial. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2018</b> , 41, 1094-1100	2.7	7
176	Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 123, 21-41	7	22
175	Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. <i>Modern Pathology</i> , <b>2018</b> , 31, 816-828	9.8	28
174	Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 639-648	21.7	47
173	Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, 93-97	13.4	191
172	Efficacy and safety of Sm-EDTMP as treatment of painful bone metastasis: a large single-center study. <i>Supportive Care in Cancer</i> , <b>2018</b> , 26, 751-758	3.9	16

171	Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study. <i>Cancer Medicine</i> , <b>2018</b> , 7, 4023-4035	4.8	27
170	Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial. <i>BMC Cancer</i> , <b>2018</b> , 18, 775	4.8	2
169	Reappraisal of eligibility criteria in cancer clinical trials. <i>Current Opinion in Oncology</i> , <b>2018</b> , 30, 352-357	4.2	2
168	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). <i>Oncologist</i> , <b>2018</b> , 23, 1407-e136	5.7	91
167	Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. <i>European Journal of Cancer</i> , <b>2018</b> , 99, 28-36	7.5	9
166	Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 11508-11508	2.2	4
165	Proof of concept: prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCR. <i>Oncotarget</i> , <b>2018</b> , 9, 18296-18308	3.3	8
164	Presentation and outcome of frequent and rare sarcoma histologic subtypes: A study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers. <i>Cancer</i> , <b>2018</b> , 124, 1179-1187	6.4	23
163	Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO). <i>Oncologist</i> , <b>2018</b> , 23, 948-955	5.7	9
162	Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial. <i>BMC Cancer</i> , <b>2018</b> , 18, 963	4.8	6
161	Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 399-406	4	12
160	Adult desmoid tumors: biology, management and ongoing trials. <i>Current Opinion in Oncology</i> , <b>2017</b> , 29, 268-274	4.2	68
159	Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). <i>European Journal of Cancer</i> , <b>2017</b> , 79, 119-128	7.5	34
158	REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis. <i>Cancer</i> , <b>2017</b> , 123, 2294-2302	6.4	30
157	Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism. <i>Case Reports in Oncological Medicine</i> , <b>2017</b> , 2017, 2683478	0.9	2
156	Lessons from three phase III trials assessing neoadjuvant treatment in sarcoma patients. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2891-2893	10.3	2
155	A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma. <i>Anti-Cancer Drugs</i> , <b>2017</b> , 28, 1157-1165	2.4	21
154	Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. <i>European Journal of Cancer</i> , <b>2017</b> , 83, 125-131	7.5	79

153	How to emerge from the conservatism in clinical research methodology?. <i>Current Opinion in Oncology</i> , <b>2017</b> , 29, 400-404	4.2	2
152	First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices. <i>Bulletin Du Cancer</i> , <b>2017</b> , 104, 552-558	2.4	2
151	A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome. <i>Scientific Reports</i> , <b>2017</b> , 7, 17917	4.9	8
150	Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 102-102	2.2	17
149	Reporting adverse events in cancer surgery randomized trials: A systematic review of published trials in oesophago-gastric and gynecological cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 104, 108-14	7	8
148	Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1732-1742	21.7	141
147	Inappropriate dose of multitargeted tyrosine kinase inhibitors: the original sin. <i>Current Opinion in Oncology</i> , <b>2016</b> , 28, 437-40	4.2	5
146	PRognostic factor of Early Death In phase II Trials or the end of 'sufficient life expectancy' as an inclusion criterion? (PREDIT model). <i>BMC Cancer</i> , <b>2016</b> , 16, 768	4.8	0
145	First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control. <i>Oncology</i> , <b>2016</b> , 90, 88-96	3.6	3
144	Crossed views of burden and emotional distress of cancer patients and family caregivers during palliative care. <i>Psycho-Oncology</i> , <b>2016</b> , 25, 1278-1285	3.9	18
143	Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1070-1080	21.7	120
142	Reply to B. Biswas and D. Dabkara. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 764-5	2.2	3
141	Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 98, 73-80	7	32
140	Trabectedin is an effective second-line treatment in soft tissue sarcoma patients. <i>Annals of Oncology</i> , <b>2016</b> , 27, 551-2	10.3	3
139	Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO). <i>Oncotarget</i> , <b>2016</b> , 7, 73984-73994	3.3	18
138	Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma. <i>BMC Cancer</i> , <b>2016</b> , 16, 679	4.8	5
137	Time interval between surgery and start of adjuvant radiotherapy in patients with soft tissue sarcoma: A retrospective analysis of 1131 cases from the French Sarcoma Group. <i>Radiotherapy and Oncology</i> , <b>2016</b> , 120, 156-62	5.3	6
136	Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. <i>European Journal of Cancer</i> , <b>2016</b> , 58, 90-6	7.5	72

135	Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue. <i>Pharmaceutical Medicine</i> , <b>2016</b> , 30, 143-147	2.3	
134	Early Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors. <i>Pharmaceutical Medicine</i> , <b>2016</b> , 30, 49-55	2.3	
133	Pain burden in desmoid tumor patients: a survey of the French Advocacy Group SOS Desmoid. <i>Bulletin Du Cancer</i> , <b>2015</b> , 102, 213-6	2.4	8
132	Omrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 531-40	21.7	42
131	Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial. <i>BMC Cancer</i> , <b>2015</b> , 15, 127	4.8	20
130	Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 457-64	21.7	70
129	Metabolic disorders associated with the use of targeted cancer therapies. <i>Current Opinion in Oncology</i> , <b>2015</b> , 27, 258-66	4.2	2
128	Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2797-802	2.2	117
127	Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). <i>Annals of Oncology</i> , <b>2015</b> , 26, 2168-73	10.3	69
126	Selection of ultimately ill cancer patients able to fulfill a questionnaire: Identification of inherent biases. <i>Bulletin Du Cancer</i> , <b>2015</b> , 102, 730-6	2.4	1
125	Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. <i>BMC Cancer</i> , <b>2015</b> , 15, 700	4.8	31
124	Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 742-50	7.5	70
123	Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 312-9	21.7	67
122	Improvement of the initial management of sarcomas after the dissemination of evidence-based guidelines depends on the primary sarcoma location: a population-based study. <i>BMC Cancer</i> , <b>2015</b> , 15, 218	4.8	6
121	Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 202-9	7.5	20
120	Molecular targeted therapies in advanced or metastatic chordoma patients: facts and hypotheses. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 95, 125-31	7	22
119	Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial. <i>Cancer</i> , <b>2015</b> , 121, 1654-61	6.4	33
118	Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 10504-10504	2.2	7



117	The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. <i>Oncotarget</i> , <b>2015</b> , 6, 26388-99	3.3	8
116	Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma. <i>Clinical and Experimental Metastasis</i> , <b>2014</b> , 31, 553-64	4.7	8
115	Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 1137-47	7.5	85
114	Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 128-36	7.5	80
113	What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials. <i>Bulletin Du Cancer</i> , <b>2014</b> , 101, E19-24	2.4	2
112	Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the competing risks setting. <i>Cancer</i> , <b>2014</b> , 120, 3361-9	6.4	50
111	The off-label use of targeted therapies in sarcomas: the OUTC'S program. <i>BMC Cancer</i> , <b>2014</b> , 14, 870	4.8	19
110	Tumor calcification: a new response pattern of myxoid liposarcoma to trabectedin. <i>Case Reports in Oncology</i> , <b>2014</b> , 7, 204-9	1	8
109	Long-term recurrence of soft tissue sarcomas: prognostic factors and implications for prolonged follow-up. <i>Cancer</i> , <b>2014</b> , 120, 3003-6	6.4	30
108	Dose-response relationship in phase I clinical trials: a European Drug Development Network (EDDN) Collaboration Study. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5663-71	12.9	11
107	Determining the length of posttherapeutic follow-up for cancer patients using competing risks modeling. <i>Medical Decision Making</i> , <b>2014</b> , 34, 168-79	2.5	3
106	Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. <i>Targeted Oncology</i> , <b>2014</b> , 9, 273-7	5	18
105	ANGIOTAX-PLUS trial: A randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 10501-10501	2.2	7
104	Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. <i>BMC Cancer</i> , <b>2013</b> , 13, 64	4.8	55
103	A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 900-9	4.3	18
102	Activity endpoints reported in soft tissue sarcoma phase II trials: quality of reported endpoints and correlation with overall survival. <i>Critical Reviews in Oncology/Hematology</i> , <b>2013</b> , 88, 309-17	7	6
101	Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). <i>Cancer</i> , <b>2013</b> , 119, 2639-44	6.4	69
100	Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review. <i>BMC Cancer</i> , <b>2013</b> , 13, 385	4.8	30

99	Localised angiosarcomas: the identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO). <i>European Journal of Cancer</i> , <b>2013</b> , 49, 369-76	7.5	18
98	Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumors. <i>Modern Pathology</i> , <b>2013</b> , 26, 502-10	9.8	34
97	Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. <i>Annals of Oncology</i> , <b>2013</b> , 24, 537-542	10.3	31
96	Regorafenib use as a possible cause of intestinal perforation. <i>Acta Oncologica</i> , <b>2013</b> , 52, 1789-90	3.2	5
95	Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2485-92	2.2	180
94	Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group. <i>Annals of Oncology</i> , <b>2013</b> , 24, 2681-2685	10.3	13
93	Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 1190-6	12.9	39
92	Nomogram to predict treatment outcome of fluoropyrimidine/platinum-based chemotherapy in metastatic esophageal squamous cell carcinoma. <i>Cancer Research and Treatment</i> , <b>2013</b> , 45, 285-94	5.2	10
91	Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2012</b> , 82, 40-50	7	99
90	Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 403-4	4.3	18
89	Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 653-61	4.3	5
88	Advanced Abrikossoff tumour: a metastatic or a multifocal malignancy?. <i>Acta Oncologica</i> , <b>2012</b> , 51, 133-5	3.2	4
87	Inflation in the number of eligibility criteria for industry-sponsored phase II cancer clinical trial: illustration over a 20-year period. <i>Contemporary Clinical Trials</i> , <b>2012</b> , 33, 459	2.3	9
86	Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 1133-40	21.7	409
85	Role of the investigator in phase 1 trials of anticancer drugs. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 1177-9	21.7	
84	Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic models. <i>Critical Reviews in Oncology/Hematology</i> , <b>2012</b> , 83, 242-8	7	14
83	Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature. <i>Critical Reviews in Oncology/Hematology</i> , <b>2012</b> , 84, 213-23	7	25
82	Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. <i>Medical Oncology</i> , <b>2012</b> , 29, 3003-8	3.7	8

81	What does a modified-Fibonacci dose-escalation actually correspond to?. <i>BMC Medical Research Methodology</i> , <b>2012</b> , 12, 103	4.7	19
80	Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?. <i>Bulletin Du Cancer</i> , <b>2012</b> , 99, 100-6	2.4	13
79	Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. <i>Cancer</i> , <b>2012</b> , 118, 3330-6	6.4	97
78	Prostate cancer related haemophagocytic syndrome: successful treatment with chemotherapy. <i>Acta Oncologica</i> , <b>2012</b> , 51, 268-9	3.2	3
77	Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 996-1004	2.2	55
76	Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). <i>Oncologist</i> , <b>2012</b> , 17, 260-6	5.7	153
75	Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). <i>Oncologist</i> , <b>2012</b> , 17, 1213-20	5.7	148
74	Solitary fibrous tumors and so-called hemangiopericytoma. <i>Sarcoma</i> , <b>2012</b> , 2012, 690251	3.1	63
73	A paradigm shift in tumour response evaluation of targeted therapy: the assessment of novel drugs in exploratory clinical trials. <i>Current Opinion in Oncology</i> , <b>2012</b> , 24, 338-44	4.2	18
72	Predictive value of clinical judgment of tumour progression in phase II trials. <i>PLoS ONE</i> , <b>2012</b> , 7, e52638	3.7	3
71	Participation in randomised clinical trials is linked to emotion regulation strategies. <i>Contemporary Clinical Trials</i> , <b>2011</b> , 32, 32-5	2.3	4
70	Radiotherapy alone for Merkel cell carcinoma: a comparative and retrospective study of 25 patients. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 65, 983-90	4.5	50
69	Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 81, e39-47	4	67
68	Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 1544-50	8.7	28
67	Adjuvant radiation therapy in metastatic lymph nodes from melanoma. <i>Radiation Oncology</i> , <b>2011</b> , 6, 12	4.2	21
66	Angiosarcoma: state of the art and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , <b>2011</b> , 80, 257-63		81
65	Factual understanding of randomized clinical trials: a multicenter case-control study in cancer patients. <i>Investigational New Drugs</i> , <b>2011</b> , 29, 700-5	4.3	6
64	Proposal for size justification of expanded cohort at phase-2-recommended dose. <i>Investigational New Drugs</i> , <b>2011</b> , 29, 713-5	4.3	4

63	Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs. <i>Investigational New Drugs</i> , <b>2011</b> , 29, 1414-9	4.3	20
62	Imaging of the most frequent superficial soft-tissue sarcomas. <i>Skeletal Radiology</i> , <b>2011</b> , 40, 271-84	2.7	26
61	Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. <i>Annals of Oncology</i> , <b>2011</b> , 22, 452-7	10.3	144
60	Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1266-1272	10.3	59
59	Pulmonary blastoma in adult: dramatic but transient response to doxorubicin plus ifosfamide. <i>Acta Oncologica</i> , <b>2011</b> , 50, 156-7	3.2	7
58	Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials. <i>PLoS ONE</i> , <b>2011</b> , 6, e16633	3.7	10
57	Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care. <i>British Journal of Cancer</i> , <b>2010</b> , 102, 1207-12	8.7	23
56	Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study. <i>JAMA Otolaryngology</i> , <b>2010</b> , 136, 1219-25		86
55	Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1361-1365	10.3	28
54	Silent hereditary hemochromatosis as a susceptibility factor of doxorubicin-induced acute cardiac failure. <i>Annals of Oncology</i> , <b>2010</b> , 21, 2293-2294	10.3	1
53	Individual life expectancy estimation using validated prognostic scores for patients with cancer of unknown primary. <i>Oncology</i> , <b>2010</b> , 78, 87-93	3.6	11
52	Palliative chemotherapy does not improve survival in metastatic esophageal cancer. <i>Oncology</i> , <b>2010</b> , 79, 46-54	3.6	16
51	Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 76-82	4.3	23
50	Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 178-84	4.3	5
49	Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 529-30	4.3	13
48	Oral metronomic cyclophosphamide in elderly with metastatic melanoma. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 684-9	4.3	32
47	Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 839-43	4.3	4
46	Head and neck cancer surgery in the elderly--does age influence the postoperative course?. <i>Oral Oncology</i> , <b>2010</b> , 46, 92-5	4.4	38

45	"Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, e105	2.2	6
44	Imatinib in gastrointestinal stromal tumor: does treatment duration matter?. <i>Oncology</i> , <b>2009</b> , 77, 157-613.6		2
43	A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3633-9	12.9	36
42	When cancerophobia and denial lead to death. <i>Palliative and Supportive Care</i> , <b>2009</b> , 7, 253-5	2.5	4
41	Vancomycin flush as antibiotic prophylaxis for early catheter-related infections: a cost-effectiveness analysis. <i>Supportive Care in Cancer</i> , <b>2009</b> , 17, 285-93	3.9	2
40	Cancer-associated hypercalcemia: validation of a bedside prognostic score. <i>Supportive Care in Cancer</i> , <b>2009</b> , 17, 1133-5	3.9	7
39	Publication biases and phase II trials investigating anticancer targeted therapies. <i>Investigational New Drugs</i> , <b>2009</b> , 27, 287-8	4.3	7
38	"Classical 3 + 3 design" versus "accelerated titration designs": analysis of 270 phase 1 trials investigating anti-cancer agents. <i>Investigational New Drugs</i> , <b>2009</b> , 27, 552-6	4.3	21
37	Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. <i>Investigational New Drugs</i> , <b>2009</b> , 27, 482-9	4.3	34
36	Soft tissue sarcomas or intramuscular haematomas?. <i>European Journal of Radiology</i> , <b>2009</b> , 72, 44-9	4.7	21
35	Development and validation of a bedside score to predict early death in cancer of unknown primary patients. <i>PLoS ONE</i> , <b>2009</b> , 4, e6483	3.7	14
34	Factors determining length of the postoperative hospital stay after major head and neck cancer surgery. <i>Oral Oncology</i> , <b>2008</b> , 44, 555-62	4.4	29
33	Additional direct medical costs associated with nosocomial infections after head and neck cancer surgery: a hospital-perspective analysis. <i>International Journal of Oral and Maxillofacial Surgery</i> , <b>2008</b> , 37, 135-9	2.9	41
32	Prognostic factors for adult sarcomas of head and neck. <i>International Journal of Oral and Maxillofacial Surgery</i> , <b>2008</b> , 37, 428-32	2.9	31
31	Primitive neuroectodermal tumour of the duodenum with unexpected lymph node involvement. <i>Scandinavian Journal of Gastroenterology</i> , <b>2008</b> , 43, 511-2	2.4	1
30	Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases. <i>Sarcoma</i> , <b>2008</b> , 2008, 459386	3.1	56
29	Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5269-74	2.2	469
28	Vinorelbine in breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2008</b> , 9, 2901-10	4	9

27	Imatinib as a possible cause of severe rhabdomyolysis. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2746-52	36
26	Prognostic factors among cancer patients with good performance status screened for phase I trials. <i>Investigational New Drugs</i> , <b>2008</b> , 26, 53-8	43 44
25	O-Mel-Inib: a Cancer of the Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. <i>Investigational New Drugs</i> , <b>2008</b> , 26, 561-5	43 42
24	Survival prognostic factors for lateral bucco-pharyngeal junction squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2008</b> , 265 Suppl 1, S25-8	35 2
23	Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis. <i>Supportive Care in Cancer</i> , <b>2008</b> , 16, 387-92	39 24
22	Development of a score that predicts survival among patients with bone metastasis revealing solid tumor. <i>Supportive Care in Cancer</i> , <b>2008</b> , 16, 1089-93	39 4
21	Factors favouring palliative treatment multidisciplinary decisions for newly diagnosed visceral and soft tissue sarcomas. <i>Clinical Oncology</i> , <b>2008</b> , 20, 523-7	28 5
20	Report of eight recent cases of locally advanced primary pulmonary artery sarcomas: failure of Doxorubicin-based chemotherapy. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 907-11	89 26
19	Risk factors for early catheter-related infections in cancer patients. <i>Cancer</i> , <b>2007</b> , 110, 1586-92	64 51
18	Prevention of surgical site infection after breast cancer surgery by targeted prophylaxis antibiotic in patients at high risk of surgical site infection. <i>Journal of Surgical Oncology</i> , <b>2007</b> , 96, 124-9	28 35
17	A simple predictive model for postoperative mortality after head and neck cancer surgery with opening of mucosa. <i>Oral Oncology</i> , <b>2007</b> , 43, 174-80	44 12
16	Quelques éléments particuliers concernant l'épidémiologie des sarcomes. <i>Oncologie</i> , <b>2007</b> , 9, 84-87	1 1
15	Angiosarcomas and taxanes. <i>Current Treatment Options in Oncology</i> , <b>2007</b> , 8, 428-34	54 32
14	General practitioners assessment of a structured report on medical decision making by a regional multidisciplinary cancer committee. <i>Bulletin Du Cancer</i> , <b>2007</b> , 94, E23-6	24 4
13	Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. <i>International Journal of Cancer</i> , <b>2006</b> , 119, 706-11	75 153
12	Primary mucosal melanoma of head and neck: prognostic value of clear margins. <i>Laryngoscope</i> , <b>2006</b> , 116, 993-5	36 63
11	Multivariate analysis of risk factors for wound infection in head and neck squamous cell carcinoma surgery with opening of mucosa. Study of 260 surgical procedures. <i>Oral Oncology</i> , <b>2005</b> , 41, 35-44	6
10	Association head and neck angiosarcoma and nevoid basal cell carcinoma syndrome (Gorlin syndrome). <i>Oral Oncology</i> , <b>2005</b> , 41, 289-291	1

9	Multivariate analysis of risk factors for wound infection in head and neck squamous cell carcinoma surgery with opening of mucosa. Study of 260 surgical procedures. <i>Oral Oncology</i> , <b>2005</b> , 41, 294-303	4.4	88
8	Prognosis of hypercalcemia in aerodigestive tract cancers: study of 136 recent cases. <i>Oral Oncology</i> , <b>2005</b> , 41, 884-9	4.4	20
7	Psychosocial factors involved in delayed consultation by patients with head and neck cancer. <i>Head and Neck</i> , <b>2005</b> , 27, 274-80	4.2	28
6	Head and neck soft tissue sarcomas of adult: prognostic value of surgery in multimodal therapeutic approach. <i>Oral Oncology</i> , <b>2004</b> , 40, 890-7	4.4	37
5	Prognostic significance of wound infections following major head and neck cancer surgery: an open non-comparative prospective study. <i>Supportive Care in Cancer</i> , <b>2004</b> , 12, 634-9	3.9	23
4	Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. <i>Supportive Care in Cancer</i> , <b>2004</b> , 12, 593-8	3.9	35
3	Previous chemotherapy as a predictor of wound infections in nonmajor head and neck surgery: Results of a prospective study. <i>Head and Neck</i> , <b>2004</b> , 26, 513-7	4.2	18
2	Risk factors for wound infection in head and neck cancer surgery: a prospective study. <i>Head and Neck</i> , <b>2001</b> , 23, 447-55	4.2	80
1	Pronostic factors of synchronous brain metastases from lung cancer. <i>Lung Cancer</i> , <b>2001</b> , 33, 143-54	5.9	44